Alteplase: Thrombolysis for acute ischemic stroke

Therapy

Volumn 2, Issue 5, 2005, Pages 709-716

  Kane, Ingrid ^a   Sandercock, Peter ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Alteplase; Ischemic stroke; Thrombolysis

Indexed keywords

ABCIXIMAB; ALTEPLASE; APROTININ; DESMOTEPLASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOLYTIC AGENT; SARUPLASE; STREPTOKINASE; TENECTEPLASE; TRANEXAMIC ACID; UROKINASE;

ACUTE DISEASE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BLEEDING DISORDER; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; EPISTAXIS; EUROPE; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEART INFARCTION; HUMAN; LICENCE; MORTALITY; MOUTH DISEASE; NONHUMAN; PHARMACODYNAMICS; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SKIN BRUISING; SYMPTOMATOLOGY; TONGUE DISEASE; TREATMENT PLANNING;

EID: 26844564688     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.2.5.709     Document Type: Review

References (34)

1. Menken M, Munsat TL, Toole JF. The Global Burden of Disease Study. Implications for neurology. Arch Neurol. 57, 418-420 (2000).
2. Gubitz G, Sandercock P, Counsell C. Antiplatelet therapy for acute ischemic stroke (Cochrane Review). In: The Cochrane Library (Issue 3). Update Software, Oxford, UK (2001).
3. Department of Health (UK). National service framework for older people modern standards and service models. London Department of Health, (2001).
4. Sinha S, Warburton EA. The evolution of stroke units - towards a more intensive approach? QJM 93, 633-638 (2000).
5. Sussman BJ. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 167, 1705-1709 (1958).
6. National Institute of Neurological Disorders and stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581-1587 (1995).
7. Johnston S. Utilization of intravenous tissue-type plasminogen activator for ischaemic stroke at academic medical centres: the influence of ethnicity. Stroke 32, 1061-1068 (2001).
8. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JJ. Treatment with tissue plasminogen activator and inpatients mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 32, 1832-1840 (2001).
9. Boehringer Ingelheim. Actilyse. Summary of product characteristics. (2002).
10. Kwan J, Leigh Brown A, Hand P, Sandercock P. In Europe, how many stroke patients can be treated with and benefit from intravenous rt-PA within 6 hours? Stroke 31, 2837 (2000) (Abstract).
11. Levine S, Gorman M. "Telestroke" the application of telemedicine for stroke. Stroke 30, 464-469 (1999).
12. Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischaemic stroke: the Cleveland area experience. JAMA 283, 1151-1158 (2000).
13. Chiu D, Krieger D, Villar-Cordova C et al. Intravenous tissue plasminogen activator for acute ischaemic stoke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 29, 18-22 (1998).
14. Hoffman JR. Tissue plasminogen activator for acute ischaemic stroke: is the CAEP Position Statement too negative? Thrombolytic therapy for acute ischeamic stroke. CJEM 3, 183-185 (2001).
15. Lenzer J. Proposed US stroke centres under fire for planned use of alteplase. BMJ 327, 247 (2003).
16. Warlow CP, Dennis MS, van Gijn J et al. Stroke. A practical guide to management. Blackwell Science 442-508 (2001).
17. Hacke W, Albers G, Al-Rawi Y et al. The desmotoplase in acute ischaemic stroke trial (DIAS). Stroke 36, 66-73 (2005).
18. Furlan A, DEDAS Investigators. Results of the dose escalation study of Desmotoplase in acute ischaemic stroke (DEDAS). Presented at: The 30th International Stroke Conference 2-4 Feb, LA, USA (2005).
19. Haley EC, Lyden PD, Johnston KC, Hemmen TM, and the TNK in stroke investigators. A pilot dose escalation safety study of tenectaplase in acute ischaemic stroke. Stroke 36, 607-612 (2005).
20. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute iscaemic stroke (Cochrane Review). In: The Cochrane Library Update software, Oxford, UK (2003).
21. Wardlaw JM, Sandercock P, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischaemic stroke. Where do we go from here? A cumulative meta-analysis. Stroke 34, 1437-1442 (2003).
22. The ATLANTIS, ECASS & NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 363, 768-774 (2005).
23. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343, 311-322 (1994).
24. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J. Clin. Epidemiol. 48, 23-40 (1995).
25. Sandercock P, Berge E, Dennis M et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischaemic stroke assessed by a model based on UK NHS costs. Stroke 35, 1490-1498 (2004).
26. Pereira A, Martin P, Warburton EA. Thrombolysis in acute ischaemic stroke. Postgrad. Med. J. 77, 166-171 (2001).
27. Clozel J, Banken L, Roux S. Aprotinin: an antidote for recombinant tissue-type plasminogen activator (rt-PA) active in vivo. J. Am. Coll. Cardiol. 16, 507-510 (1990).
28. Kase C, Pessin M, Zivin J. Intracranial haemorrhage after coronary thrombolysis with tissue plasminogaen activator. Am. J. Med. 92, 384-390 (1992).
29. Ludlam C, Bennet B, Fox K, Lowe G, Reid A. Guidelines for the use of thrombolytic therapy. Blood Coagul Fibrinolysis 6, 273-285 (1995).
30. Hill M, Lye T, Moss H et al. Hemiorolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 60, 1525-1527 (2003).
31. Brown A. Anaphylaxis. In: Oxford Textbook of Medicine. Warrell DA, Cox TM, Firth JD, Benz Jr EJ (Eds), Oxford University Press, Oxford, UK 1233-1237 (2003).
32. Hill M, Barber P, Takahashi J, Demchuk A, Feasby T, Buchan A. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischaemic stroke. Can. Med. Assoc. J. 162, 1281-1284 (2000).
33. Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment. Stroke 33, 1712-1716 (2002).
34. Innes K. Thrombolysis for acute ischaemic stroke: core nursing requirements. Br J. Nurs. 12, 416-424 (2003).